Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Stevanato Group S.p.A.NYSE: STVN

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin dips below year-ago levels

Q2 FY2026 selling, general & admin of €31.7M fell 1.2% year over year, behind the +3.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.

Context

  • Selling, general & admin amounted to 10.8% of revenue in FY2025, unchanged from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 10 analysts of €133.6M (+8.7%) for the fiscal year ending Dec 2026, a step up from the +3.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€31.7M+5.8% QoQ
Last fiscal yearDec 2025
€122.85M+3.6% YoY
LTMJun 2026
€126.68M+3.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.2%+12.2%+13.4 pp
1 year+3.6%+8.7%+5.2 pp
3-year CAGR+3.2%+6.4%+3.2 pp
5-year CAGR+8.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

EUR · from the income statement

Latest · FY2025
122.85M EUR
Year-over-year change
+3.6%
4-year CAGR
+10.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.9% is the 7th highest of 11, against a peer median of +7.3%.
  • Selling, general & admin amounts to 10.4% of revenue for STVN, versus a peer median of 29.9%.
STVN Competitors
Selling, General & Admin for STVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$2.22B USD+1.8%+14.8%41.8%
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$1.36B USD+7.5%+2.8%8.9%
AVTRAvantor, Inc.LTM Jun 2026$1.2B USD-26.2%+2.7%18.3%
TFXTeleflex IncorporatedLTM Jun 2026$943.66M USD+0.4%-5.9%36.3%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$712.67M USD+55.0%+53.0%91.8%
ATRAptarGroup, Inc.LTM Jun 2026$634.83M USD+8.2%-2.8%16.1%
MASIMasimo CorporationLTM Apr 2026$530M USD-18.7%-8.4%34.0%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$481.78M USD+9.7%+9.9%29.9%
CHEChemed CorporationLTM Jun 2026$440.8M USD+7.2%+5.2%17.0%
STVNStevanato Group S.p.A.LTM Jun 2026€126.68M EUR+3.9%+3.2%10.4%
NUVLNuvalent, Inc.LTM Mar 2026$122.74M USD+77.8%+68.6%—
Peer median (excluding STVN) —+7.3%+4.0%29.9%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue843.92M983.68M1.09B1.1B1.14B
Cost of Revenue578.52M663.88M745.46M801.72M809.15M
Gross Profit265.41M319.8M339.89M302.32M330.33M
Gross Margin31.4%32.5%31.3%27.4%29.0%
Research & Development29.62M34.39M35.67M31.67M24.4M
Selling, General & Admin82.95M111.83M113.92M118.6M122.85M
Operating Expenses103.18M127.37M139.17M141.18M147.25M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
EBITDA226.93M256.4M272.35M247.8M292.01M
EBITDA Margin26.9%26.1%25.1%22.4%25.6%
Operating Income162.23M192.43M200.72M161.14M183.08M
Operating Margin19.2%19.6%18.5%14.6%16.1%
Interest Income548K648K792K1.72M12.49M
Interest Expense4.87M3.94M4.32M6.86M21.8M
Other Income / Expenses3.45M(4.79M)(11.17M)(854K)(1.44M)
Income Before Tax165.67M187.64M189.55M160.29M181.64M
Pre-Tax Margin19.6%19.1%17.5%14.5%15.9%
Income Tax Expense31.4M44.63M43.86M42.52M47.35M
Net Income134.32M142.85M145.63M117.78M134.28M
Net Margin15.9%14.5%13.4%10.7%11.8%
EPS (Basic)0.530.530.550.430.49
EPS (Diluted)0.530.530.550.430.49
Weighted Avg Shares264.7M264.7M264.95M272.87M273M
Weighted Avg Shares (Diluted)264.7M264.7M264.98M272.88M273M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.